89bio Stock (NASDAQ:ETNB)
Previous Close
$9.14
52W Range
$6.88 - $16.63
50D Avg
$8.11
200D Avg
$9.14
Market Cap
$983.90M
Avg Vol (3M)
$547.66K
Beta
0.99
Div Yield
-
ETNB Company Profile
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
ETNB Performance
Peer Comparison
Ticker | Company |
---|---|
PLRX | Pliant Therapeutics, Inc. |
AKRO | Akero Therapeutics, Inc. |
XFOR | X4 Pharmaceuticals, Inc. |
TGTX | TG Therapeutics, Inc. |
MREO | Mereo BioPharma Group plc |
DAWN | Day One Biopharmaceuticals, Inc. |
STOK | Stoke Therapeutics, Inc. |
HOOK | HOOKIPA Pharma Inc. |
TERN | Terns Pharmaceuticals, Inc. |
VKTX | Viking Therapeutics, Inc. |
INZY | Inozyme Pharma, Inc. |
ACLX | Arcellx, Inc. |
ABOS | Acumen Pharmaceuticals, Inc. |
HEPA | Hepion Pharmaceuticals, Inc. |
MDGL | Madrigal Pharmaceuticals, Inc. |